On the other hand, isolated reports noted that some NSCLC patients with ALK rearrangements or EGFR mutations had low response rates to PD-1/PD-L1 inhibitors, possibly due to low PD-L1 expression and low levels of infiltrating CD8+T lymphocytes in tumors [55]. Here, ALK is linked to non-small cell lung carcinoma.